Advertisement
Organisation › Details
Glox Therapeutics Ltd.
Glox Therapeutics is developing a pipeline of engineered precision bacteriocins targeting pathogens that cause serious infections associated with high levels of antimicrobial resistance (AMR) and mortality. These novel precision antibiotics have potent narrow-spectrum activity to target Gram-negative AMR pathogens without collateral damage to the wider human microbiome. Founded in 2023, the Company is built out of over 20+ years of research from globally recognised expertise in elucidating bacteriocin structure and function to treat bacterial infections. It is uniquely positioned to address the AMR public health crisis which is predicted to surpass 10 million deaths globally per year at a cost of $100 trillion dollars by 2050. *
Start | 2023-02-27 established (s-off) | |
Predecessor | University of Glasgow | |
Industry | antibiotic | |
Industry 2 | drug development | |
Person | Clark, James (Glox Therapeutics 202311 CEO) | |
Region | Glasgow | |
Country | United Kingdom (GB) | |
Street | University Avenue The Square 11,, University of Glasgow | |
City | G12 8QQ Glasgow, Scotland | |
Address record changed: 2023-11-16 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Glox Therapeutics Ltd.. (11/14/23). "Press Release: Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria". Glasgow. | ||
Record changed: 2023-11-16 |
Advertisement
More documents for Glox Therapeutics Ltd.
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top